On discounting of health gains from human papillomavirus vaccination: Effects of different approaches

Value in Health

Volumn 15, Issue 3, 2012, Pages 562-567

  Westra, Tjalke A ^a   Parouty, Mehraj ^b   Brouwer, Werner B ^c   Beutels, Philippe H ^d   Rogoza, Raina M ^e   Rozenbaum, Mark H ^b   Daemen, Toos ^a   Wilschut, Jan C ^a   Boersma, Cornelis ^b   Postma, Maarten J ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e OPTUM   (United States)

Author keywords

discounting; health gains; HPV vaccination; QALY

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS MODEL; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PATIENT PREFERENCE; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84861163792     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.01.005     Document Type: Article

References (40)

1. S. Simoens Health economic assessment: a methodological primer Int J Environ Res Public Health 6 2009 2950 2966
2. M.F. Drummond, M.J. Sculpher, G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes (3rd ed.) 2005 Oxford University Press Oxford
3. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein Cost-effectiveness in Health and Medicine 1996 Oxford University Press Oxford
4. ISPOR Pharmacoeconomics guidelines http://www.ispor.org/peguidelines/ index.asp [Accessed April 1, 2011]
5. R.M. Rogoza, T.A. Westra, N. Ferko Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands Vaccine 27 2009 4776 4783
6. M.J. Mangen, Y.T. van Duynhoven, H. Vennema Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 28 2010 2624 2635
7. M. Brisson, N. Van de Velde, P. De Wals, M.C. Boily The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada Vaccine 25 2007 5399 5408 (Pubitemid 46977529)
8. A. Tasset, V.H. Nguyen, S. Wood, K. Amazian Discounting: technical issues in economic evaluations of vaccination Vaccine 17 Suppl. 3 1999 S75 S80
9. P. Beutels, W.J. Edmunds, F. Antonanzas Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis Pharmacoeconomics 20 2002 1 7 (Pubitemid 34155211)
10. P. Beutels, P.A. Scuffham, C.R. MacIntyre Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 8 2008 727 733
11. H. Bleichrodt, W. Brouwer Discounting M.P.M.H. Rutten-vanMölken, J.J. Busschbach van, F.F.H. Rutten, Van Kosten tot Effecten Een handleiding voor evaluatiestudies in de gezondheidszorg 2000 Elsevier Maarssen
12. E.B. Keeler, S. Cretin Discounting of life-saving and other non-monetary effects Manage Sci 29 1983 300 306
13. K. Claxton, M. Sculpher, A. Culyer Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion Health Econ 15 2006 1 4 (Pubitemid 43141521)
14. J.A. Olsen Time preferences for health gains: an empirical investigation Health Econ 2 1993 257 265
15. A. Lazaro Theoretical arguments for the discounting of health consequences: where do we go from here? Pharmacoeconomics 20 2002 943 961 (Pubitemid 35398694)
16. B.J. Cohen Discounting in cost-utility analysis of healthcare interventions: reassessing current practice Pharmacoeconomics 21 2003 75 87 (Pubitemid 36127004)
17. B.A. van Hout Discounting costs and effects: a reconsideration Health Econ 7 1998 581 594 (Pubitemid 28521897)
18. W. Brouwer, B. van Hout, F. Rutten A fair approach to discounting future effects: taking a societal perspective J Health Serv Res Policy 5 2000 114 118 (Pubitemid 30195332)
19. W.B. Brouwer, L.W. Niessen, M.J. Postma, F.F. Rutten Need for differential discounting of costs and health effects in cost effectiveness analyses BMJ 331 2005 446 448 (Pubitemid 41176388)
20. W.B. Brouwer, N.J. van Exel Discounting in decision making: the consistency argument revisited empirically Health Pol 67 2004 187 194 (Pubitemid 38068216)
21. R.M. Klok, W.B.F. Brouwer, L.J.P. Annemans Towards a healthier discount procedure Expert Rev Pharmacoecon Outcomes Res 5 1 2005 59 63 (Pubitemid 40590124)
22. M.M. Van Der Pol, J.A. Cairns Negative and zero time preference for health Health Econ 9 2000 171 175 (Pubitemid 30148163)
23. M. van der Pol, J. Cairns Estimating time preferences for health using discrete choice experiments Soc Sci Med 52 2001 1459 1470 (Pubitemid 32175700)
24. J.A. Cairns, M.M. van der Pol Saving future lives: a comparison of three discounting models Health Econ 6 1997 341 350 (Pubitemid 27384639)
25. F. Asenso-Boadi, T.J. Peters, J. Coast Exploring differences in empirical time preference rates for health: an application of meta-regression Health Econ 17 2008 235 248 (Pubitemid 351265997)
26. J. Cairns, M. van der Pol Constant and decreasing timing aversion for saving lives Soc Sci Med 45 1997 1653 1659 (Pubitemid 27511335)
27. C. Harvey Proportional discounting of future health gains: an empirical investigation Health Econ 20 1995 18
28. G.F. Loewenstein, D. Prelec Anomalies in intertemporal choice: evidence and an interpretation Q J Econ 107 1992 573 597
29. M. van der Pol, J. Cairns Descriptive validity of alternative intertemporal models for health outcomes: an axiomatic test Health Econ 20 2011 770 782
30. B. Bazelon Discounting in the long term Loyala Los Angeles Law Rev 35 2002 277
31. Oxera A social time preference rate for use in long-term discounting http://www.oxera.com [Accessed January 1, 2011]
32. J.M. Bos, P. Beutels, L. Annemans, M.J. Postma Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases Pharmacoeconomics 22 2004 1171 1179 (Pubitemid 40075719)
33. M. Drummond, C. Chevat, M. Lothgren Do we fully understand the economic value of vaccines? Vaccine 25 2007 5945 5957 (Pubitemid 47082460)
34. W.J. Meerding, G.J. Bonsel, W.B. Brouwer Social time preference for health and money elicited with a choice experiment Value Health 13 2010 368 374
35. M. Jit, M. Brisson Modelling the epidemiology of infectious diseases for decision analysis: a primer Pharmacoeconomics 29 2011 371 386
36. J.F. O'Mahony, I.M. de Kok, J. van Rosmalen Practical implication of differential discounting in cost-effectiveness analysis with varying numbers of cohorts Value Health 14 4 2011 438 442
37. T.A. Westra, M.B. Parouty, J.C. Wilschut Practical implication of differential discounting of costs and health effects in cost-effectiveness analysis Value Health 14 8 2011 1173 1174
38. J.F. O'Mahony, I.M. de Kok, J. van Rosmalen Practical implication of differential discounting of costs and health effects in cost-effectiveness analysis Value Health 14 8 2011 1174 1175
39. A. Bobinac, W. Brouwer, J. van Exel Discounting future health gains: an empirical enquiry into the influence of growing life expectancy Health Econ 20 2011 111 119
40. National Institute of Clinical Excellence http://www.nice.org.uk [Accessed January 1, 2012]